GlassScriptPhysician profile
Carly Swint
NPI 1407374408
$7,851.66
in general payments reported to CMS, 2019-2025
31 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,690 · 2022: $611 · 2023: $854 · 2024: $2,327 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Consulting Fee: $1,471 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.34 |
| Consulting Fee | $1,471.49 |
| Education | $166.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,874.02 | 2021-2025 | Hyqvia, Takhzyro, Glassia |
| Csl Behring | $1,659.01 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Octapharma USA, INC. | $875.86 | 2021-2023 | Cutaquig, Panzyga |
| Grifols USA, LLC | $524.86 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Cycle Pharmaceuticals INC | $413.93 | 2021-2025 | Sajazir |
| Pharming Healthcare, INC. | $291.66 | 2021-2025 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $282.78 | 2021-2025 | Tezspire, Fasenra |
| Adma Biomanufacturing LLC | $235.24 | 2023 | |
| Biocryst US Sales Co., LLC | $215.71 | 2021-2024 | Orladeyo |
| Genzyme Corporation | $213.17 | 2021-2025 | |
| Ionis Pharmaceuticals, INC. | $206.56 | 2025 | Dawnzera, Donidalorsen |
| Catalyst Pharmaceuticals, INC. | $173.94 | 2021-2025 | |
| Bio Products Laboratory USA, INC. | $130.20 | 2022-2023 | Gammaplex, Coagadex |
| Amgen INC. | $120.95 | 2022-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $111.09 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $99.99 | 2023 | |
| Paratek Pharmaceuticals, INC. | $58.53 | 2021 | |
| Kedrion Biopharma, INC. | $50.42 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Genentech USA, INC. | $47.67 | 2022-2024 | Xolair |
| Kaleo, INC. | $43.06 | 2021-2024 | Auvi-Q |
| Abbvie INC. | $28.43 | 2021 | |
| Sobi, INC | $26.40 | 2023 | |
| Glaxosmithkline, LLC. | $26.28 | 2021-2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $24.49 | 2025 | Neffy |
| Biogen, INC. | $19.26 | 2024 | Aduhelm |
| Teva Pharmaceuticals USA, INC. | $18.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.37 | 2024 | Keveyis |
| Nestle Healthcare Nutrition INC. | $18.17 | 2021 | |
| Organon LLC | $15.10 | 2025 | Vtama |
| Lundbeck LLC | $15.04 | 2022 | |
| Tersera Therapeutics LLC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Swint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.